Uric acid as a marker of pathophysiological mechanisms in patients with cardiovascular disease;Patofysiologiske mekanismer bag urats prognostiske betydning ved kardiovaskulær sygdom

Ugeskrift for Laeger

Volumn 167, Issue 40, 2005, Pages 3771-3774

  Calberg, Maiken J ^a   Kjøller, Erik ^a  

^a Amtssygehuset i Herlev   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BIOLOGICAL MARKER; URIC ACID; XANTHINE OXIDASE;

CARDIOVASCULAR DISEASE; CATALYSIS; HEART MUSCLE ISCHEMIA; HUMAN; PATHOPHYSIOLOGY; PERIPHERAL ISCHEMIA; PROGNOSIS; REVIEW; URIC ACID BLOOD LEVEL;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL ISCHEMIA; PROGNOSIS; URIC ACID;

EID: 26444583357     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Wannamethee SG. Serum uric acid is not an independent risk factor for coronary heart disease. Curr Hypertens Rep 2001;3:190-6.
2. Bickel C, Rupprecht HJ, Blankenberg S et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:12-7.
3. Anker SD, Doehner W, Rauchhaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-7.
4. Pedersen AB, Kjøller E, Jørgensen S et al. Serum uric acid as a prognostic marker in patients with acute myocardial infarction and left vetricular dysfunction. Eur J Heart Fail 2000;2:63.
5. Moorhouse PC, Grootveld M, Halliwell B et al. Allopurinol and oxypurinol are hydroxyl radical scavengers. FEBS Lett 1987;213:23-8.
6. de Jong JW, van der Meer P, Nieukoop AS et al. Xanthine oxidoreductase activity in perfused hearts of various species, including humans. Circ Res 1990;67:770-3.
7. Nielsen VG, Tan S, Baird MS et al. Xanthine oxidase mediates myocardial injury after hepatoenteric ischemia-reperfusion. Crit Care Med 1997;25:1044-50.
8. Saavedra WF, Paolocci N, St John ME et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002;90:297-304.
9. Bolli R. Oxygen-derived free radicals and postischemic myocardial dysfunction (»stunned myocardium«). J Am Coll Cardiol 1988;12:239-49.
10. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985;312:159-63.
11. Huizer T, de Jong JW, Nelson JA et al. Urate production by human heart. J Mol Cell Cardiol 1989;21:691-5.
12. De Scheerder IK, van de Kraay AM, Lamers JM et al. Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanisms for free radical generation. Am J Cardiol 1991;68:392-5.
13. Lazzarino G, Raatikainen P, Nuutinen M et al. Myocardial release of malondialdehyde and purine compounds during coronary bypass surgery. Circulation 1994;90:291-7.
14. Grum CM, Ketai LH, Myers CL et al. Purine efflux after cardiac ischemia: relevance to allopurinol cardioprotection. Am J Physiol 1987;252:H368-73.
15. Gimpel JA, Lahpor JR, van der Molen AJ et al. Reduction of reperfusion injury of human myocardium by allopurinol: a clinical study. Free Radic Biol Med 1995;19:251-5.
16. Castelli P, Condemi AM, Brambillasca C et al. Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery. J Cardiovasc Pharmacol 1995;25:119-25.
17. Ekelund UE, Harrison RW, Shokek O et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999;85:437-45.
18. De Jong JW, Schoemaker RG, de Jonge R et al. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol 2000;32:2083-9.
19. Cappola TP, Kass DA, Nelson GS et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407-11.
20. Bakhtiiarov ZA. Changes in xanthine oxidase activity in patients with circulatory failure. Ter Arkh 1989;61:68-9.
21. Leyva F, Anker S, Swan JW et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;18:858-65.
22. Perez NG, Gao WD, Marban E. Novel myofilament Ca2+-sensitizing property of xanthine oxidase inhibitors. Circ Res 1998;83:423-30.
23. Perez NG, Hashimoto K, McCune S et al. Origin of contractile dysfunction in heart failure: calcium cycling versus myofilaments. Circulation 1999;99:1077-83.
24. Maxwell AJ, Bruinsma KA. Uric acid is closely linked to vascular nitric oxide activity. J Am Coll Cardiol 2001;38:1850-8.
25. Doehner W, Rauchhaus M, Florea VG et al. Uric acid in cachectic and non-cachectic patients with chronic heart failure: relationship to leg vascular resistance. Am Heart J 2001;141:792-9.
26. Doehner W, Schoene N, Rauchhaus M et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002;105:2619-24.
27. Leyva F, Anker SD, Godsland IF et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998;19:1814-22.
28. Facchini F, Chen YD, Hollenbeck CB et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991;266:3008-11.
29. Leyva F, Chua TP, Godsland IF et al. Loss of the normal coupling between the anaerobic threshold and insulin sensitivity in chronic heart failure. Heart 1999;82:348-51.
30. Patetsios P, Song M, Shutze WP et al. Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am J Cardiol 2001;88:188-91.
31. Sanchez-Lozada LG, Tapia E, Avila-Casado C et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002;283:F1105-10.
32. Waring WS, Webb DJ, Maxwell SR. Effect on local hyperuricaemia on endothelial function in the human forearm vascular bed. Br J Pharmacol 2000;49:511.
33. Bagnati M, Perugini C, Cau C et al. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J 1999;340:143-52.
34. Mustard JF, Murphy EA, Ogryzlo MA et al. Blood coagulation and platelet economy in subjects with primary gout. Can Med Assoc J 1963;89:1207-11.
35. Hare JM, Johnson RJ. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 2003;107:1951-3.